Vikram Khurana, MD, PhD

Vikram Khurana is Chief of the Division of Movement Disorders at Massachusetts General and Brigham and Women’s Hospitals, where he leads the Harvard Biomarkers Study/MyTrial research programs. His research focuses on understanding diverse clinical outcomes in Parkinson’s and related disorders with a view to developing patient-targeted therapies. The Khurana lab deploys molecular tools to dissect protein-misfolding mechanisms in nervous system cell types. The team integrates genetic interaction mapping, proximity labeling, and computational analysis to construct molecular networks of alpha-synucleinopathy, uncovering links to RNA-binding proteins, cellular stress pathways, and innate immunity. Novel iPSC models accelerating alpha-synuclein pathologies are being used in the group to study gene-environment interactions and to discover new alpha-synuclein radiotracers and therapeutics. The MyTrial program has enabled simultaneous testing of drug in patients and matched stem cells. Dr. Khurana is a co-inventor on multiple patents, including for novel drug classes in clinical development, and co-founded two biotechnology companies.